Andrew Berens
Stock Analyst at Leerink Partners
(1.93)
# 2,631
Out of 5,090 analysts
101
Total ratings
51.14%
Success rate
-2.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Upgrades: Outperform | $40 → $34 | $27.73 | +22.61% | 12 | Nov 20, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $140 → $149 | $109.60 | +35.95% | 3 | Nov 17, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $50 | $38.77 | +28.97% | 6 | Nov 10, 2025 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $6.40 | +134.38% | 1 | Oct 31, 2025 | |
| MRUS Merus | Downgrades: Market Perform | $95 → $97 | $96.14 | +0.89% | 6 | Oct 6, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $13.69 | +82.62% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $105.63 | -43.20% | 2 | Jul 28, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $12.79 | -29.63% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $5.53 | +8.50% | 3 | Apr 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Market Perform | $880 → $762 | $718.36 | +6.07% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.06 | +978.43% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $26.69 | -6.33% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $121.22 | -20.81% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $102.52 | -23.92% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $18.09 | +54.78% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $90.18 | -12.40% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.39 | +1,842.45% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $10.59 | +136.07% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $6.43 | +522.08% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $2.67 | +2,409.36% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $17.41 | +14.88% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $9.63 | +159.61% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $12.58 | -36.41% | 7 | Jul 14, 2017 |
Agios Pharmaceuticals
Nov 20, 2025
Upgrades: Outperform
Price Target: $40 → $34
Current: $27.73
Upside: +22.61%
Nuvalent
Nov 17, 2025
Maintains: Outperform
Price Target: $140 → $149
Current: $109.60
Upside: +35.95%
Cogent Biosciences
Nov 10, 2025
Maintains: Outperform
Price Target: $18 → $50
Current: $38.77
Upside: +28.97%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $6.40
Upside: +134.38%
Merus
Oct 6, 2025
Downgrades: Market Perform
Price Target: $95 → $97
Current: $96.14
Upside: +0.89%
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $13.69
Upside: +82.62%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $105.63
Upside: -43.20%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $12.79
Upside: -29.63%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $5.53
Upside: +8.50%
Regeneron Pharmaceuticals
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $718.36
Upside: +6.07%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $3.06
Upside: +978.43%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $26.69
Upside: -6.33%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $121.22
Upside: -20.81%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $102.52
Upside: -23.92%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $18.09
Upside: +54.78%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $90.18
Upside: -12.40%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.39
Upside: +1,842.45%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $10.59
Upside: +136.07%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $6.43
Upside: +522.08%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.67
Upside: +2,409.36%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $17.41
Upside: +14.88%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $9.63
Upside: +159.61%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $12.58
Upside: -36.41%